OncoMatch/Clinical Trials/NCT03936478
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
Is NCT03936478 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer that will: 1) significantly reduce the duration of treatment and can be completed in one-week (5 working days) and 2) MRI-guided radiotherapy (MRIdian) would limit the volume of normal tissue radiated and therefore resultant toxicity. The hypothesis is that 3-fraction radiation therapy can be delivered safely without compromising the therapeutic ratio. Participants can expect to be on study for follow up up to 5 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Excluded: BRCA1 mutation positivity
BRCA1/2 mutation positivity
Excluded: BRCA2 mutation positivity
BRCA1/2 mutation positivity
Allowed: ESR1 negative
ER (-) [cautionary pathologic factor]
Disease stage
Required: Stage TIS (TNM)
T Stage: Tis or T1 (suitable); T2 (cautionary); Pure DCIS ≤3 cm if 'suitable' criteria not fully met
Demographics
Prior therapy
Cannot have received: hormonal agent (raloxifene, tamoxifen, aromatase inhibitor, selective estrogen receptor modulator)
Concurrent therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, Aromatase Inhibitors or other selective estrogen receptor modulators (SERMs), either for osteoporosis or breast cancer prevention or neoadjuvant therapy
Cannot have received: radiation therapy
Prior breast or thoracic radiotherapy for any condition or treatment plan that includes regional nodal irradiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Wisconsin Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03936478 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hormonal agent, radiation therapy disqualifies patients from enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation positivity is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation positivity is an exclusion criterion.
What disease stage is eligible?
Stage TIS is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages